GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES-A REVIEW

Reshma Ramesan* and Dr. Sruthy Renjan

ABSTRACT

Targeting the incretin system has become an important therapeutic approach for treating type 2 diabetes. In people with type 2 diabetes mellitus (T2DM), the incretin effect is reduced, but the recent advent of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide (GLP)-1 agonists/analogues has enabled restoration of at least some of the function of the incretin system, with accompanying improvements in glycaemic control.[1] The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. Two GLP-1 receptor agonists/analogues are currently approved for the treatment of T2DM— exenatide (Byetta®, Eli Lilly & Co., Indianapolis, IN, US) and liraglutide (Victoza®, Novo Nordisk, Bagsvaerd, Denmark); a once-weekly formulation of exenatide (Bydureon®, Eli Lilly & Co.) has also been approved by the European Medicines Agency. This review aims to investigate the effectiveness of GLP-1 analogues in patients with type 2 diabetes mellitus who are not achieving satisfactory glycaemic control with one or more oral glucose lowering drugs.[1,2]

Keywords: Targeting the incretin system has become an important therapeutic approach for treating type 2 diabetes.